Cardiovascular disease (CVD) is one of the primary causes of death among patients with chronic kidney disease (CKD) 1 . Thus, prevention of CVD is an important priority in the comprehensive care of patients with CKD. As hypertension is a cause of both CKD and CVD, decreasing blood pressure (BP) has the potential to slow CKD progression, prevent CVD events and prolong survival.
antihypertensive therapy -such as acute kidney injury (AKI) and syncope -result in death from non-CVD causes.
The findings of the meta-analysis are consistent with those of the SPRINT trial, which tested whether an intensive systolic blood pressure (SBP) goal of <120 mmHg was more effective for primary prevention of CVD than a standard SBP goal of <140 mmHg in a high-risk group of adults without diabetes, including patients with CKD (a subgroup comprising 30% of the participants) 3 . The trial was terminated early because of a reduced risk of both CVD and all-cause mortality in the intensive BP group.
In SPRINT, the benefits of the more intensive BP goal were similar in the CKD and non-CKD subgroups, based on the lack of statistically significant interactions between randomized goal and CKD status. The beneficial effect of intensive BP lowering on allcause mortality occurred despite a more rapid decline in estimated glomerular filtration rate (eGFR) and an increased incidence of AKI in the intensive compared with the standard BP group 4 . The main finding from this meta-analysis -reduction in all-cause mortality -has important implications for patients with CKD. However, certain caveats exist, with perhaps the most important being potential less-intensive BP control reduces the risk of all-cause mortality in adults with stage 3-5 CKD (OR 0.86, 95% CI 0.76-0.97) 2 (TABLE 1) .
The meta-analysis identified 18 trials, including the SPRINT study, that examined the relationship of intensive BP control with mortality in patients with stage 3-5 CKD 2 . In this meta-analysis, all-cause mortality was chosen as the end point because CVD benefits might not translate into improved survival if potential adverse effects of intensive Hypertension is a risk factor for chronic kidney disease (CKD), but the optimal blood pressure (BP) target in patients with stage 3-5 CKD is unclear. Now, a meta-analysis reports that more-intensive BP control is associated with a reduced risk of all-cause mortality compared with less-intensive BP goals in this high-risk population. Further exploration of heterogeneity is needed to identify those patients with CKD who will benefit from intensive BP-lowering therapy as well as to plan subsequent trials in subgroups for which the evidence of benefit is uncertain, in particular patients with CKD and diabetes.
A second important issue is the relatively short duration of the follow-up period. The median follow-up of trials included in the meta-analysis was only 3.6 years, so potential long-term effects of intensive BP goals could not be examined.
Two trials -the MDRD trial 5, 6 and the AASK trial 7 -provide some evidence of extended benefit of intensive BP lowering in patients with CKD. Although the initial trial period of these studies was included in the meta-analysis, the extended follow-up period was not.
MDRD enrolled 840 adults with eGFR of 13-55 ml/min/1.73 m 2 , who were randomly assigned to either an intensive or standard BP goal 5 . The intensive BP goal was a mean arterial pressure (MAP) ≤92 mmHg for adults 18-60 years (similar to 125/75 mmHg) or ≤98 mmHg for adults ≥61 years (similar to 145/75 mmHg), whereas the standard BP goal was ≤107 mmHg (similar to 140/90 mmHg) for adults 18-60 years or ≤113 mmHg (similar to 160/90 mmHg) for adults ≥61 years. MDRD documented that the intensive BP goal was associated with a nonsignificant, increased risk of death over a mean of 2.2 years of follow-up (HR 1.37, 95% CI 0.68-2.74). However, extended follow-up (~10 years) revealed that the intensive BP goal was associated with reduced risk of kidney failure or death (HR 0.77, 95% CI 0.65-0.91) 6 . AASK enrolled 1,094 African-American adults with CKD attributed to hyper tension. Participants were randomly assigned to either a MAP goal of ≤92 mmHg (intensive BP group) or a MAP goal of 102-107 mmHg (standard BP group) 7 . No significant betweengroup difference in death was reported during the trial phase with mean follow-up of 3.8 years (HR 0.75, 95% CI 0.49-1.15). However, over extended follow-up, which ranged from 8.8-12.2 years, intensive BP lowering was associated with a significantly reduced risk of death (HR 0.81, 95% CI 0.68-0.98). Together, MDRD 5 and AASK 7 demonstrate a long-term mortality benefit of intensive BP lowering in CKD, beyond the relatively brief duration of studies included in the meta-analysis.
In conclusion, the results of the metaanalysis by Malhotra et al. are consistent with findings from the SPRINT study, which documented increased survival from intensive BP lowering in non-diabetic adults with CKD. Whether these findings apply to adults with diabetes and CKD is uncertain, and trials of intensive versus standard BP goals in this high-risk group are warranted.
